
Albumin-induced inactivation of lung surfactants

RET Intern: Danielle Petrey, funded by NSF Mentor: Patrick Stenger PI: Joe Zasadzinski Funding: NIH


What is lung surfactant?


- Lipid and protein mixture lining the 600 million alveoli of the lungs
- LS modulates surface tension during breathing cycle; prevents alveolar collapse
- Reduces work of breathing
- Prevents water droplets from blocking airways




Components of lung surfactant

- 35-40% dipalmitoyl phosphatidylcholine (DPPC), a phospholipid
- 30-45% other phospholipids
- 5-10% protein (SP-A, B, C, D)
- Cholesterols (neutral lipids)







http://persweb.wabash.edu/facstaff/fellers/image.html

What is surface tension?

- Tendency of molecules in a fluid to be pulled toward the center of the fluid
- Measured as energy/unit area (J/m²) or force across a line (N/m)
- Surface tension of water is 72 mN/m; with LS can drop to 2mN/m or lower
- Surface pressure (Π) = amount surface tension
 (σ) is lowered by surfactant film (Π= σ° σ)

Background

NRDS

ARDS

- Premature infants lack LS in NRDS (reduced lung compliance and oxygenation)
- Replacement LS reduces infant mortality due to NRDS from 165.2/100,000 (1979) to 24.6/100,000 (2000)
- FDA-approved LS includes Survanta (bovine), Curosurf (porcine), and Infasurf (calf)


- ARDS 1.5-8.4 cases/100,000; mortality 30%
- Variety of causes results in inactivation of LS
- LS replacement unsuccessful in treating patients
- Surface-active albumin (serum protein) is elevated in alveolar fluid of ARDS patients


Goals of project


- Identify a repeatable experiment to determine effect of albumin on model LS
- Explore different aspects of adsorption to interface
- Long term goal: design synthetic replacement LS

Methods: How we study surface tension

- Langmuir-Wilhelmy force balance and Teflon trough with expandable barriers
- Isotherms varies pressure by expanding and compressing barriers to study behavior of surfactants
- Surfactant is spread on an aqueous subphase (from solvent or from solution)







Procedures


Comparison of three different LS


1) 500uL Infasurf suspension

3) 6uL simulated Infasurf (in CHCL₃:MeOH) lipids only, (simple model)

2) 20uL/7.5uL Infasurf, lyophilized and reconstituted in 2:1 CHCl₃:MeOH
20 components (complex model including proteins)

Results: Infasurf (aq) and inactivation








Inhibition results in: 1) lower surface pressure (inhibiting LS to lower surface tension) 2) low plateau

Albumin concentration study


Inconsistency resulting from suspension delivery (expect concentration dependency)











Infasurf in solvent













Infasurf (solvent) monolayer and inactivation experiment







•Based on minimum molecular area (40A²/mol), 7.5uL is a monolayer

Lose plateau at 40mN/m


•Compare 2nd cycles, 1st cycles are odd






Simulated Infasurf and inhibition


Components: 45.7% DPPC 28.6% POPC 17.1% POPG 2.9% POPE 5.7% Cholesterol







Concentration inhibition study:

- max surface pressures decrease with increasing [albumin]
- plateau is lower with
 - increasing [albumin]







Conclusions

- Infasurf inactivated entirely when spread by aqueous - (1000 μg)
- Infasurf not inactivated when spread from solvent (large concentrations) – (40 μg)
- Infasurf somewhat inactivated when spread from solvent (small concentrations)